# Study of ANAVEX2-73 in Patients With Rett Syndrome

> **NCT03758924** · PHASE2 · COMPLETED · sponsor: **Anavex Life Sciences Corp.** · enrollment: 31 (actual)

## Conditions studied

- Rett Syndrome

## Interventions

- **DRUG:** ANAVEX2-73
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03758924
- **Lead sponsor:** Anavex Life Sciences Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-28
- **Primary completion:** 2020-10-30
- **Final completion:** 2020-10-30
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03758924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03758924, "Study of ANAVEX2-73 in Patients With Rett Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03758924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*